Ordenar

Buscar

01/09/2025 Azathioprine for the Treatment of Chronic Spontaneous Urticaria Refractory to Antihistamines, Omalizumab, and Ciclosporin: A Case Series
Mateu-Arrom, L, Martin, R, Expósito-Serrano, V, Alvarez-Abella, A, Serra-Baldrich, E, Spertino, J. Azathioprine for the Treatment of Chronic Spontaneous Urticaria Refractory to Antihistamines, Omalizumab, and Ciclosporin: A Case Series. Actas Dermo-Sifiliograficas. 2025; 116(8)DOI:10.1016/j.ad.2025.05.022. PMID:40480489. IF:(Q/D).
01/09/2025 Similarity of efficacy of SB17 to reference ustekinumab for moderate-to-severe psoriasis through 12 weeks in different demographic and comorbidity subgroups
Feldman, SR, Sanz, LP, Girolomoni, G, Jo, SJ, Jung, H, Jung, J. Similarity of efficacy of SB17 to reference ustekinumab for moderate-to-severe psoriasis through 12 weeks in different demographic and comorbidity subgroups. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2025; 93(3)DOI:. PMID:. IF:11.800(Q1/1D).
01/09/2025 Bimekizumab achievement of 'super response' using a previously published definition in moderate to severe plaque psoriasis: Results from four phase 3/3b trials
Lebwohl, M, Langley, RG, Strober, B, Thaçi, D, Armstrong, A, Gordon, KB, Puig, L, Davies, O, Peterson, L, Davis, L, Warren, RB. Bimekizumab achievement of 'super response' using a previously published definition in moderate to severe plaque psoriasis: Results from four phase 3/3b trials. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2025; 93(3)DOI:. PMID:. IF:11.800(Q1/1D).
01/09/2025 Towards Defining Follow-up Strategies for Patients with Primary Intermediate-risk Non-muscle-invasive Bladder Cancer
Contieri, R, Martini, A, Beijert, IJ, Mertens, LS, Hentschel, AE, Brundl, J, Compérat, EM, Plass, K, Rodríguez, O, Henríquez, JDS, Hernández, V, de la Pena, E, Alemany, I, Turturica, D, Pisano, F, Soria, F, Capoun, O, Bauerova, L, Pesl, M, Bruins, HM, Runneboom, W, Herdegen, S, Breyer, J, Brisuda, A, Calatrava, A, Rubio-Briones, J, Seles, M, Mannweiler, S, Bosschieter, J, Kusuma, VRM, Ashabere, D, Huebner, N, Seisen, T, Claps, F, Masson-Lecomte, A, Liedberg, F, Cohen, D, Lunelli, L, Cussenot, O, El Sheikh, S, Volanis, D, Cote, JF, Roupret, M, Haitel, A, Shariat, SF, Mostafid, AH, Nieuwenhuijzen, JA, Zigeuner, R, Dominguez-Escrig, JL, Hacek, J, Zlotta, AR, Burger, M, Evert, M, van de Kaa, CA, van der Heijden, AG, Kiemeney, LALM, Soukup, V, Molinaro, L, Hurle, R, Paciotti, M, Moschini, M, Pradere, B, Perdona, S, Gontero, P, Llorente, C, Algaba, F, Palou, J, N'Dow, J, Ribal, MJ, van der Kwast, TH, Babjuk, M, Sylvester, RJ, van Rhijn, BWG. Towards Defining Follow-up Strategies for Patients with Primary Intermediate-risk Non-muscle-invasive Bladder Cancer. European Urology Oncology. 2025; 8(4)DOI:10.1016/j.euo.2025.04.010. PMID:40399193. IF:9.300(Q1/1D).
01/09/2025 Clinical features of children with MOG-IgG who fulfill criteria of multiple sclerosis and overlapping disorders
Perez, EGF, Olivé, G, Chen, LW, Paredes-Carmona, F, Nuñez-Enamorado, N, Duran, SB, Mendibe, MD, Visa-Reñe, N, Vasquez-Lopez, M, Felipe-Rucián, A, Romeu, G, Martinez, E, Blanco, Y, Sepulveda, M, Saiz, A, Dalmau, J, Armangue, T. Clinical features of children with MOG-IgG who fulfill criteria of multiple sclerosis and overlapping disorders. Multiple Sclerosis Journal. 2025; 31(3)DOI:. PMID:. IF:5.000(Q1/2D).
01/09/2025 Edge-to-edge tricuspid valve repair and heart failure hospitalizations: the TRI-SPA registry
Echarte-Morales, J, Sanchis, L, Arzamendi, D, Moñivas, V, Carrasco-Chinchilla, F, Pan, MN, Nombela-Franco, L, Pascual, I, Benito-González, T, Pérez, R, Gomez-Blázquez, I, Amat-Santos, IJ, Cruz-González, I, Sánchez-Recalde, A, Alvarez, ABC, Barreiro-Pérez, M, Cepas-Guillén, P, Li, CH, del Trigo, M, Martinez-Carmona, JD, Mesa, D, Mahia, P, Avanzas, P, González-Garcia, A, Freixa, X, Estévez-Loureiro, R. Edge-to-edge tricuspid valve repair and heart failure hospitalizations: the TRI-SPA registry. REVISTA ESPANOLA DE CARDIOLOGIA. 2025; 78(9)DOI:10.1016/j.rec.2025.02.015. PMID:40154922. IF:4.900(Q1/2D).
01/09/2025 Hypochloremia in chronic and acute heart failure scenarios: Prevalence and risk factors
Llàcer, P, Marcos, MC, Croset, F, Zegri-Reiriz, I, de la Espriella, R, Ordás, JG, Forti, A, Rubio-Graciaj, J, Blazquez-Bermejo, Z, Mendez, A, Rodriguez, A, Caravaca-Perez, P, Comin-Colet, J, Morales-Rull, JL, Manzano, L, Núñez, J. Hypochloremia in chronic and acute heart failure scenarios: Prevalence and risk factors. European Journal of Internal Medicine. 2025; 139DOI:10.1016/j.ejim.2025.05.022. PMID:40500604. IF:6.100(Q1/1D).
01/09/2025 Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop
Kimmoun, A, O'Brien, C, Blumer, V, Wenzl, FA, Pöss, J, Zeymer, U, Moller, JE, Aissaoui, N, Sinha, SS, Combes, A, Sato, N, Sionis, A, Soussi, S, Price, S, Monroe, RE, Mathew, R, Mebazaa, A. Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop. Lancet Respiratory Medicine. 2025; 13(9)DOI:10.1016/S2213-2600(25)00084-0. PMID:40339587. IF:32.800(Q1/1D).